Association of Screen Time With Physical and Mental Health in University Students: Systematic Review and Meta-Analysis.

J Med Internet ResOct 26, 2026 (epub)

Gongbinxuan Wu, Claire Eades, Louise Hoyle

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined screen-time duration and physical and mental health outcomes in university students aged 17 years or older. Across 82 studies (83 independent samples; 161,340 participants), longer screen time was associated with poorer health overall (r=0.175, 95% CI 0.133-0.217; P<.001). Associations were similar for mental and physical health, but varied by specific outcome: the association was strongest for depression, while estimates for well-being, stress, and weight-related outcomes were not statistically significant. Between-study heterogeneity was substantial.

Key findings

  • Overall, longer screen time was associated with poorer health (k=83; r=0.175, 95% CI 0.133-0.217; P<.001).
  • The association was strongest for depression (k=21; r=0.230, 95% CI 0.167-0.291); well-being was not significantly associated (k=7; r=0.040, 95% CI -0.146 to 0.223).
  • Screen time was associated with poorer sleep quality (k=26; r=0.120, 95% CI 0.083-0.158) and eye health outcomes (k=16; r=0.277, 95% CI 0.089-0.446).
  • Heterogeneity was substantial (I 2 =98.35%), and study-level moderators did not meaningfully explain it.

Why it matters

The findings suggest that screen-time duration is associated with several health outcomes in university students, but the strength of association differs across outcomes. This distinction matters when interpreting broad claims about screen use: pooled results do not imply uniform effects across physical and mental health, and the substantial heterogeneity limits how precisely the overall estimate applies to particular student populations or outcomes.

What to keep in mind

The predominance of cross-sectional studies and reliance on self-reported screen time limit causal inference. Evidence was sparse for some outcomes, and substantial heterogeneity remained unexplained.

Source

Published in J Med Internet Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.